Myriad is proud to announce our successful collaboration with two Irish consortia that secured over €21 million in DTIF 7 funding, including support for what has become the largest funded project in DTIF history.

This achievement represents not only a significant business milestone for Myriad but also a substantial investment in Ireland's position as a global leader in healthcare innovation and clinical trials.

The N-LIFT project, led by LlfT Biosciences, with a consortium of HookeBio and the University of Galway focuses on advancing a white blood cell cancer therapy, using Immuno-Modulatory Alpha Neutrophils (IMANs). IMANS are designed to overcome treatment resistance in solid cancer tumours with a unique dual purpose that both directly kills cancer cells and recruits the rest of the immune system to identify tumours and destroy them.

At €12 million, N-LIFT represents the DTIF’s largest award since the programme’s inception in 2018.

A second project that Myriad supported, VentriPump, was awarded €9.3 million. The consortium of CardiacBooster, Integer Holdings and FIRE1 will use this funding to develop the gold standard heart pump to support heart function during cardiogenic shock.

More winners in Call 7 are expected to be announced in the coming weeks.

Funding Innovation in Ireland with the DTIF

The Disruptive Technologies Innovation Fund (DTIF) is an Irish government-backed, €500 million fund, overseen by the Department of Enterprise, Trade and Employment and administered by Enterprise Ireland.

It aims to accelerate industrial research and experimental development (TRL 3–9) through collaborative consortia of at least three, involving at least one SME and another enterprise partner.

Applications are assessed against four key criteria: disruptiveness, quality of approach, economic impact and sustainability, and collaboration strength.

The total funding awarded is now up to €422 million across 110 projects and 7 DTIF calls.

This substantial investment positions Ireland as a hub for disruptive technology development and R&D, attracting international attention and fostering a thriving innovation ecosystem that benefits from strong government backing and industry collaboration.

Projects Already Funded in DTIF’s Call 7

Though more winners in DTIF’s Call 7 will be announced shortly, the Irish government has announced that three projects, totalling €28 million in funding, have been successful. The following winning projects, both a collaboration with Myriad, demonstrate the forefront of the Irish medical device field.

N-LIFT: Revolutionary Cancer Treatment (€12 Million)

Each year, 4 million Europeans are diagnosed with cancer, and 1.9 million die from the disease. Solid tumours represent approximately 90% of adult human cancers and metastatic disease is responsible for 90% of deaths from solid tumours.

LIfT’s Immuno-Modulatory Alpha Neutrophils (IMANs) are made from the cells of donors with exceptional cancer-killing white blood cells, using LIfT’s proprietary infusion therapy platform, known as N-LIfT. The vision is to develop the world's first cell bank of off-the-shelf cancer-killing and immunomodulatory white blood cells to deliver a portfolio of cell therapies for solid tumour indications. This approach could dramatically reduce treatment timelines and costs while improving outcomes for thousands of cancer patients.

VentriPump: Advanced Cardiac Support System (€9.3 Million)

When hearts fail due to chronic conditions or heart attacks, some vital organs may starve of oxygen due to the lower amount of blood making it around the body. This is called cardiogenic shock (CS) and has an alarmingly high rate of mortality, almost 50%, even at the most advanced medical institutions in the world.

When recovering, the heart needs to be given time to recover in the short term, usually through mechanical intervention with a heart pump, or percutaneous ventricular assist device (pVAD). The consortium of CardiacBooster, Integer Holdings and FIRE1 will develop an entire treatment that meets the gold standard for treating CS, including a novel pVAD to offload the heart and a remote monitoring system to assess recovery results. VentriPump will make it possible to save hundreds of thousands of lives.

Myriad’s Role in Securing Funding

Myriad's success in securing funding for two groundbreaking healthcare projects stems from our long-standing relationships with some of Ireland's most innovative companies, particularly in the medical technology sector.

Our previous collaboration with consortium partners has been particularly valuable. We have worked with CardiacBooster and Hooke Bio on earlier projects, including securing €5.5 million for Hooke Bio's drug-testing platform.

Myriad recognises that each project represents years of research, development, and vision from dedicated teams working to solve some of society's most pressing challenges. Our role is to effectively communicate this vision and demonstrate how proposed solutions align with DTIF objectives and assessment criteria.

Hear It Directly From The Winners

"Marc Greatrex and the Myriad team have been instrumental in helping us to secure DTIF funding for the development of a novel medical device platform to treat cardiogenic shock. I would highly recommend Marc and his team to anyone looking to apply for grant funding."

Florian Ludwig, CEO at CardiacBooster

“I have collaborated with Marc on a number of projects and he, along with his team at Myriad, have demonstrated a deep understanding and professional approach towards the grant funding ecosystem. He is very knowledgeable of the requirements, and his track record speaks for itself.”

Richard Gribbons, Director of R&D at Integer Holdings

The Future of the DTIF

Further winners of DTIF funding in Call 7 are expected to be announced shortly.

Many innovative companies may now be looking forward to the next DTIF call, due to be announced later this year.

If you’re looking for support for your proposal or if you need advice on innovation funding, get in touch with our team. From homegrown funding like the DTIF, European pots like Horizon Europe, and even R&D tax credits, Myriad is your guide to financing your innovation.